In the paper, results indicated that Wogonin potentiated the inhibitory effect of IM on CML cells in BM microenvironment, and may be an attractive drug by targeting Stat5 directly to overcome resistance to BCR/ABL kinase inhibitors. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.